BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 25314639)

  • 21. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
    Cho YA; Yoon HJ; Lee JI; Hong SP; Hong SD
    Oral Oncol; 2011 Dec; 47(12):1148-53. PubMed ID: 21911310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
    Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
    Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.
    Chapon M; Randriamampita C; Maubec E; Badoual C; Fouquet S; Wang SF; Marinho E; Farhi D; Garcette M; Jacobelli S; Rouquette A; Carlotti A; Girod A; Prévost-Blondel A; Trautmann A; Avril MF; Bercovici N
    J Invest Dermatol; 2011 Jun; 131(6):1300-7. PubMed ID: 21346771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
    Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
    World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
    Droeser RA; Hirt C; Viehl CT; Frey DM; Nebiker C; Huber X; Zlobec I; Eppenberger-Castori S; Tzankov A; Rosso R; Zuber M; Muraro MG; Amicarella F; Cremonesi E; Heberer M; Iezzi G; Lugli A; Terracciano L; Sconocchia G; Oertli D; Spagnoli GC; Tornillo L
    Eur J Cancer; 2013 Jun; 49(9):2233-42. PubMed ID: 23478000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
    Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
    Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aligning digital CD8
    Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
    Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
    Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
    J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
    BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases.
    Batur S; Dulger O; Durak S; Yumuk PF; Caglar HB; Bozkurtlar E; Bozkurt S; Tastekin E; Cicin I; Ahiskali R; Rzazade R; Cakir A; Oz B
    Bosn J Basic Med Sci; 2020 Aug; 20(3):329-335. PubMed ID: 31999935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
    Rodić N; Anders RA; Eshleman JR; Lin MT; Xu H; Kim JH; Beierl K; Chen S; Luber BS; Wang H; Topalian SL; Pardoll DM; Taube JM
    Cancer Immunol Res; 2015 Feb; 3(2):110-5. PubMed ID: 25370533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.
    Ju X; Shen R; Huang P; Zhai J; Qian X; Wang Q; Chen M
    Oncotarget; 2017 Nov; 8(59):99372-99381. PubMed ID: 29245908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
    Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
    Kakavand H; Vilain RE; Wilmott JS; Burke H; Yearley JH; Thompson JF; Hersey P; Long GV; Scolyer RA
    Mod Pathol; 2015 Dec; 28(12):1535-44. PubMed ID: 26403784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.